FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113313274> ?p ?o ?g. }

• W2113313274 endingPage "745.e12" @default.
• W2113313274 startingPage "745.e1" @default.
• W2113313274 abstract "BackgroundSince 1995 uterine artery embolization has been described as an alternative for hysterectomy in patients with symptomatic fibroids. Many studies including several randomized controlled trials established uterine artery embolization as a valuable treatment. These randomized controlled trials reported outcomes in terms of health-related quality of life, clinical outcomes, efficacy, and cost-effectiveness after 1, 2, and 5 years of follow-up.ObjectiveThe purpose of this study was to compare clinical outcome and health-related quality of life 10 years after uterine artery embolization or hysterectomy in the treatment of heavy menstrual bleeding caused by uterine fibroids in a randomized controlled trial.Study DesignIn all, 28 Dutch hospitals recruited patients with symptomatic uterine fibroids who were eligible for hysterectomy. Patients were 1:1 randomly assigned to uterine artery embolization or hysterectomy. The outcomes assessed at 10 years postintervention were reintervention rates, health-related quality of life, and patient satisfaction, which were obtained through validated questionnaires. Study outcomes were analyzed according to original treatment assignment (intention to treat).ResultsA total of 177 patients were randomized from 2002 through 2004. Eventually 81 uterine artery embolization and 75 hysterectomy patients underwent the allocated treatment shortly after randomization. The remaining patients withdrew from the trial. The 10-year questionnaire was mailed when the last included patient had been treated 10 years earlier. The mean duration of follow-up was 133 months (SD 8.58) accompanied by a mean age of 57 years (SD 4.53). Questionnaires were received from 131 of 156 patients (84%). Ten years after treatment, 5 patients underwent secondary hysterectomy resulting in a total of 28 of 81 (35%) (24/77 [31%] after successful uterine artery embolization). Secondary hysterectomies were performed for persisting symptoms in all cases but 1 (for prolapse). After the initial treatment health-related quality of life improved significantly. After 10 years, generic health-related quality of life remained stable, without differences between both groups. The urogenital distress inventory and the defecation distress inventory showed a decrease in both groups, probably related to increasing age, without significant differences between study arms. Satisfaction in both groups remained comparable. The majority of patients declared being (very) satisfied about the received treatment: 78% of the uterine artery embolization group vs 87% in the hysterectomy group.ConclusionIn about two thirds of uterine artery embolization–treated patients with symptomatic uterine fibroids a hysterectomy can be avoided. Health-related quality of life 10 years after uterine artery embolization or hysterectomy remained comparably stable. Uterine artery embolization is a well-documented and less invasive alternative to hysterectomy for symptomatic uterine fibroids on which eligible patients should be counseled. Since 1995 uterine artery embolization has been described as an alternative for hysterectomy in patients with symptomatic fibroids. Many studies including several randomized controlled trials established uterine artery embolization as a valuable treatment. These randomized controlled trials reported outcomes in terms of health-related quality of life, clinical outcomes, efficacy, and cost-effectiveness after 1, 2, and 5 years of follow-up. The purpose of this study was to compare clinical outcome and health-related quality of life 10 years after uterine artery embolization or hysterectomy in the treatment of heavy menstrual bleeding caused by uterine fibroids in a randomized controlled trial. In all, 28 Dutch hospitals recruited patients with symptomatic uterine fibroids who were eligible for hysterectomy. Patients were 1:1 randomly assigned to uterine artery embolization or hysterectomy. The outcomes assessed at 10 years postintervention were reintervention rates, health-related quality of life, and patient satisfaction, which were obtained through validated questionnaires. Study outcomes were analyzed according to original treatment assignment (intention to treat). A total of 177 patients were randomized from 2002 through 2004. Eventually 81 uterine artery embolization and 75 hysterectomy patients underwent the allocated treatment shortly after randomization. The remaining patients withdrew from the trial. The 10-year questionnaire was mailed when the last included patient had been treated 10 years earlier. The mean duration of follow-up was 133 months (SD 8.58) accompanied by a mean age of 57 years (SD 4.53). Questionnaires were received from 131 of 156 patients (84%). Ten years after treatment, 5 patients underwent secondary hysterectomy resulting in a total of 28 of 81 (35%) (24/77 [31%] after successful uterine artery embolization). Secondary hysterectomies were performed for persisting symptoms in all cases but 1 (for prolapse). After the initial treatment health-related quality of life improved significantly. After 10 years, generic health-related quality of life remained stable, without differences between both groups. The urogenital distress inventory and the defecation distress inventory showed a decrease in both groups, probably related to increasing age, without significant differences between study arms. Satisfaction in both groups remained comparable. The majority of patients declared being (very) satisfied about the received treatment: 78% of the uterine artery embolization group vs 87% in the hysterectomy group. In about two thirds of uterine artery embolization–treated patients with symptomatic uterine fibroids a hysterectomy can be avoided. Health-related quality of life 10 years after uterine artery embolization or hysterectomy remained comparably stable. Uterine artery embolization is a well-documented and less invasive alternative to hysterectomy for symptomatic uterine fibroids on which eligible patients should be counseled." @default.
• W2113313274 created "2016-06-24" @default.
• W2113313274 creator A5000135344 @default.
• W2113313274 creator A5007693618 @default.
• W2113313274 creator A5014568603 @default.
• W2113313274 creator A5023843843 @default.
• W2113313274 creator A5061955049 @default.
• W2113313274 creator A5064972239 @default.
• W2113313274 creator A5066967483 @default.
• W2113313274 date "2016-12-01" @default.
• W2113313274 modified "2023-10-17" @default.
• W2113313274 title "Uterine artery embolization vs hysterectomy in the treatment of symptomatic uterine fibroids: 10-year outcomes from the randomized EMMY trial" @default.
• W2113313274 cites W1227345485 @default.
• W2113313274 cites W1542775365 @default.
• W2113313274 cites W1980661472 @default.
• W2113313274 cites W2023725358 @default.
• W2113313274 cites W2031932600 @default.
• W2113313274 cites W2032920408 @default.
• W2113313274 cites W2033952229 @default.
• W2113313274 cites W2041567260 @default.
• W2113313274 cites W2065927741 @default.
• W2113313274 cites W2067258086 @default.
• W2113313274 cites W2078237173 @default.
• W2113313274 cites W2105882735 @default.
• W2113313274 cites W2121595753 @default.
• W2113313274 cites W2128457669 @default.
• W2113313274 cites W2132154428 @default.
• W2113313274 cites W2132458770 @default.
• W2113313274 cites W2146309723 @default.
• W2113313274 cites W2152367884 @default.
• W2113313274 cites W2153717621 @default.
• W2113313274 cites W2159997952 @default.
• W2113313274 cites W2170045968 @default.
• W2113313274 cites W2912049116 @default.
• W2113313274 cites W4253890724 @default.
• W2113313274 doi "https://doi.org/10.1016/j.ajog.2016.06.051" @default.
• W2113313274 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27393268" @default.
• W2113313274 hasPublicationYear "2016" @default.
• W2113313274 type Work @default.
• W2113313274 sameAs 2113313274 @default.
• W2113313274 citedByCount "194" @default.
• W2113313274 countsByYear W21133132742012 @default.
• W2113313274 countsByYear W21133132742013 @default.
• W2113313274 countsByYear W21133132742014 @default.
• W2113313274 countsByYear W21133132742015 @default.
• W2113313274 countsByYear W21133132742016 @default.
• W2113313274 countsByYear W21133132742017 @default.
• W2113313274 countsByYear W21133132742018 @default.
• W2113313274 countsByYear W21133132742019 @default.
• W2113313274 countsByYear W21133132742020 @default.
• W2113313274 countsByYear W21133132742021 @default.
• W2113313274 countsByYear W21133132742022 @default.
• W2113313274 countsByYear W21133132742023 @default.
• W2113313274 crossrefType "journal-article" @default.
• W2113313274 hasAuthorship W2113313274A5000135344 @default.
• W2113313274 hasAuthorship W2113313274A5007693618 @default.
• W2113313274 hasAuthorship W2113313274A5014568603 @default.
• W2113313274 hasAuthorship W2113313274A5023843843 @default.
• W2113313274 hasAuthorship W2113313274A5061955049 @default.
• W2113313274 hasAuthorship W2113313274A5064972239 @default.
• W2113313274 hasAuthorship W2113313274A5066967483 @default.
• W2113313274 hasBestOaLocation W21133132741 @default.
• W2113313274 hasConcept C126322002 @default.
• W2113313274 hasConcept C131872663 @default.
• W2113313274 hasConcept C141071460 @default.
• W2113313274 hasConcept C159110408 @default.
• W2113313274 hasConcept C168563851 @default.
• W2113313274 hasConcept C204243189 @default.
• W2113313274 hasConcept C2776035437 @default.
• W2113313274 hasConcept C2779234561 @default.
• W2113313274 hasConcept C2779494336 @default.
• W2113313274 hasConcept C2779607476 @default.
• W2113313274 hasConcept C2779951463 @default.
• W2113313274 hasConcept C2780566971 @default.
• W2113313274 hasConcept C2781207646 @default.
• W2113313274 hasConcept C46973012 @default.
• W2113313274 hasConcept C535046627 @default.
• W2113313274 hasConcept C54355233 @default.
• W2113313274 hasConcept C71924100 @default.
• W2113313274 hasConcept C86803240 @default.
• W2113313274 hasConceptScore W2113313274C126322002 @default.
• W2113313274 hasConceptScore W2113313274C131872663 @default.
• W2113313274 hasConceptScore W2113313274C141071460 @default.
• W2113313274 hasConceptScore W2113313274C159110408 @default.
• W2113313274 hasConceptScore W2113313274C168563851 @default.
• W2113313274 hasConceptScore W2113313274C204243189 @default.
• W2113313274 hasConceptScore W2113313274C2776035437 @default.
• W2113313274 hasConceptScore W2113313274C2779234561 @default.
• W2113313274 hasConceptScore W2113313274C2779494336 @default.
• W2113313274 hasConceptScore W2113313274C2779607476 @default.
• W2113313274 hasConceptScore W2113313274C2779951463 @default.
• W2113313274 hasConceptScore W2113313274C2780566971 @default.
• W2113313274 hasConceptScore W2113313274C2781207646 @default.
• W2113313274 hasConceptScore W2113313274C46973012 @default.
• W2113313274 hasConceptScore W2113313274C535046627 @default.
• W2113313274 hasConceptScore W2113313274C54355233 @default.
• W2113313274 hasConceptScore W2113313274C71924100 @default.
• W2113313274 hasConceptScore W2113313274C86803240 @default.

• next